Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Industry Urges Quick Adoption Of Accelerated Access Proposals As Brexit Clouds Gather

Executive Summary

UK review proposes key changes to the way that new medicines and medical technologies are identified, developed and adopted for use in the National Health Service, including an Accelerated Access Partnership of stakeholders that will manage the accelerated pathway to patients, a new government unit to discuss commercial arrangements, and a “transformative designation” to flag up products of greatest interest.

You may also be interested in...

Post-Brexit, Could A Sector Deal Boost UK Life Sciences?

Government proposals to provide a boost for the UK’s industrial base to counter the disruption likely from Brexit include “sector deals” between companies and government, new funds for innovation, and encouraging later-stage venture capital financing, all of which are likely already on the wish-list of companies in the life sciences sector.

BIA Says NHS Funding Changes Would Jeopardize Life Science Sector, As UK PM Announces ‘Hard’ Brexit

As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.

Coronavirus Notebook: COVAX Wellcomes Latecomers, Sanofi/GSK Sign Canadian Supply Deal

The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts